DAR-901
Candidate Overview
DAR-901 is an inactivated whole cell vaccine derived from a non-tuberculous mycobacterium and represents a scalable manufacturing process for SRL172.
Sponsor / Lead Developer: Dartmouth, St. Louis University
Primary Indication: Prevention of TB disease
Target Population(s): Adolescents, Adults, and People living with HIV
Target Route of Administration: Intradermal
Clinical Trials
COMPLETED TRIALS |
|
| Registry Number | NCT02712424 |
| Clinical Trial Phase | Phase 2b |
| Clinical Sponsor | Dartmouth-Hitchcock Medical Center |
| Primary endpoint(s) for this clinical trial | Prevention of Mtb infection or sustained infection |
| Target population(s) for clinical trial | Adolescents |
| People without Mtb infection | |
_________________________ |
|
| Registry Number | NCT02063555 |
| Clinical Trial Phase | Phase 1 |
| Clinical Trial Sponsor | Dartmouth-Hitchcock Medical Center |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
| People living with HIV | |
| People without HIV | |
Related Publications
- DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial (Vaccine, 2020)
- CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial (PLOS One, 2019)
- Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901 (PLOS ONE,
- Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis (PLOS ONE, 2016)
- Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine (AIDS, 2010)